| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/12/2012 | US20120009123 Albumin binding peptide-mediated disease targeting |
| 01/12/2012 | US20120006716 Humanized anti-il-6 antibodies |
| 01/12/2012 | US20120006323 Nasal devices |
| 01/12/2012 | CA2840079A1 Compositions and methods for treating influenza |
| 01/12/2012 | CA2804686A1 Dual variable domain immunoglobulins and uses thereof |
| 01/12/2012 | CA2804666A1 Methods of immune modulation |
| 01/12/2012 | CA2804604A1 Designer peptide-based pcv2 vaccine |
| 01/12/2012 | CA2804591A1 Cationic oil-in-water emulsions |
| 01/12/2012 | CA2804494A1 Virion-like delivery particles for self-replicating rna molecules |
| 01/12/2012 | CA2804492A1 Immunisation of large mammals with low doses of rna |
| 01/12/2012 | CA2804399A1 Anti-ron antibodies |
| 01/12/2012 | CA2804396A1 Liposomes with lipids having an advantageous pka-value for rna delivery |
| 01/12/2012 | CA2804242A1 Cancer therapy using cldn6 target-directed antibodies in vivo |
| 01/12/2012 | CA2804127A1 Cancer peptide vaccine |
| 01/12/2012 | CA2804029A1 Ceramide-like glycolipid-associated bacterial vaccines and uses thereof |
| 01/12/2012 | CA2803900A1 Combinations of kinase inhibitors for the treatment of cancer |
| 01/12/2012 | CA2802443A1 Vaccine compositions based on sticholysin encapsulated in liposomes |
| 01/12/2012 | CA2799934A1 Respiratory syncytial virus antigenic compositions and methods |
| 01/11/2012 | EP2405004A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 01/11/2012 | EP2405003A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 01/11/2012 | EP2404936A1 Cancer therapy using CLDN6 target-directed antibodies in vivo |
| 01/11/2012 | EP2404935A1 Immunoglobulin binding HOSM |
| 01/11/2012 | EP2404933A2 HBV variants detection and application |
| 01/11/2012 | EP2404927A2 Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma |
| 01/11/2012 | EP2404616A2 Binding proteins specific for insulin-like growth factors and uses thereof |
| 01/11/2012 | EP2404615A1 Humanized antibodies to interferon alpha receptor-1 (IFNAR-1) |
| 01/11/2012 | EP2404614A1 Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| 01/11/2012 | EP2403963A1 A biomarker and treatment for cancer |
| 01/11/2012 | EP2403943A1 Vangl1 peptides and vaccines including the same |
| 01/11/2012 | EP2403935A1 Compositions comprising angiogenic factors and methods of use thereof |
| 01/11/2012 | EP2403879A1 Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
| 01/11/2012 | EP2403878A1 Fully human antibodies specific to cadm1 |
| 01/11/2012 | EP2403871A1 Antibodies and epitopes specific to misfolded prion protein |
| 01/11/2012 | EP2403868A1 Cloning and recombinant production of vespula venom protease and methods of use thereof |
| 01/11/2012 | EP2403867A2 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essential consisting of vp3 |
| 01/11/2012 | EP2403605A2 Secreted ap2 and methods of inhibiting same |
| 01/11/2012 | EP2403532A2 Humanized anti-cd19 antibody formulations |
| 01/11/2012 | EP2403531A2 Il-17 binding proteins |
| 01/11/2012 | EP2403530A2 Engineered proteins with high affinity for dota chelates |
| 01/11/2012 | EP2403529A1 Anti-rhesus d monoclonal antibody |
| 01/11/2012 | EP2403528A2 Antibodies against a proliferating inducing ligand (april) |
| 01/11/2012 | EP2403527A2 Live attenuated influenza virus vaccines comprising microrna response elements |
| 01/11/2012 | EP2403526A2 Chlamydia antigens |
| 01/11/2012 | EP2403525A2 Attenuated salmonella enterica serovar paratyphi a and uses thereof |
| 01/11/2012 | EP2403524A1 Antibody drug conjugates (adc) that bind to 24p4c12 proteins |
| 01/11/2012 | EP2403507A1 Treatment of infection |
| 01/11/2012 | EP2086578B1 Use of clostridium perfringens type c bacterium for the manufacture of a vaccine |
| 01/11/2012 | EP1737489B1 ErbB2 antagonists for tumor pain therapy |
| 01/11/2012 | EP1608399B1 Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex |
| 01/11/2012 | EP1572121B1 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 01/11/2012 | EP1572074B1 Stabilized synthetic immunogen delivery system |
| 01/11/2012 | EP1565210B1 Clostridial neurotoxin for use in the treatment of nasal congestion |
| 01/11/2012 | EP1511845B1 Immunostimulatory oligonucleotides and uses thereof |
| 01/11/2012 | EP1401497B1 Methods for the modulation of il-13 |
| 01/11/2012 | EP1370288B1 Method for treating thrombocytopenia with monoclonal ivig |
| 01/11/2012 | EP1248648B1 Vaccination against canine herpesvirus infection and vaccines |
| 01/11/2012 | EP1019432B1 The ob receptor and methods of diagnosing and treating weight |
| 01/11/2012 | EP0975672B1 Antibodies for inhibiting blood coagulation and methods of use thereof |
| 01/11/2012 | CN1997385B Annexin V for preventing atherothrombois and plaque rupture |
| 01/11/2012 | CN1934448B Method for the prevention of malaria |
| 01/11/2012 | CN1934134B Methods for inducing autolysis in infectious bacteria |
| 01/11/2012 | CN1930188B Estrogen receptors and methods of use |
| 01/11/2012 | CN102317469A GNAQ mutations in melanoma |
| 01/11/2012 | CN102317449A Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV |
| 01/11/2012 | CN102317439A Live attenuated vaccines |
| 01/11/2012 | CN102317318A Anti-CD160 monoclonal antibodies and uses thereof |
| 01/11/2012 | CN102317308A Virus like particle compositions and methods of use |
| 01/11/2012 | CN102316899A Use of an immunoglobulin G (IgG) concentrate depleted of anti-A and anti-B antibodies for treating neonatal jaundice caused by maternal-foetal incompatibility with respect to the ABO system |
| 01/11/2012 | CN102316898A Anti-CD147 antibodies, methods, and uses |
| 01/11/2012 | CN102316897A Notch-binding agents and antagonists and methods of use thereof |
| 01/11/2012 | CN102316896A Vaccine |
| 01/11/2012 | CN102316895A Vaccine against highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS) |
| 01/11/2012 | CN102316894A Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains |
| 01/11/2012 | CN102316854A Solid compositions |
| 01/11/2012 | CN102311986A Cells producing antibody compositions |
| 01/11/2012 | CN102311972A Method for preparing Porcine circovirus type 2 antigen with chloroplast and its product |
| 01/11/2012 | CN102311957A Hydatidovis soluble antigen preparation method and product thereof |
| 01/11/2012 | CN102311928A Recombinant yeast engineering strain coexpressed by proteins of chicken anaemia viruses VP1 and VP2, construction method thereof and application thereof |
| 01/11/2012 | CN102311499A Humanized monoclonal antibody for treating cancer, and preparation method and application thereof |
| 01/11/2012 | CN102309759A Poultry freeze-drying live vaccine heat-resisting protective agent and preparation method thereof |
| 01/11/2012 | CN102309757A Novel regulatory factor of FOXP3 and regulatory T cells, and use thereof |
| 01/11/2012 | CN102309755A Design scheme for compound type dual duplex locating type intracellular vaccine |
| 01/11/2012 | CN102309754A Stable medicinal composition of recombinant humanized antibody |
| 01/11/2012 | CN102309753A Riemerella anatipestifer serum 1 type, 2 type and 4 type trivalent oil emulsion inactivated vaccine |
| 01/11/2012 | CN101947321B Heat-resisting and freeze-drying protector for live vaccine and preparation method thereof as well as live newcastle disease vaccine |
| 01/11/2012 | CN101914502B I-type canine adenovirus attenuated vaccine strain and application thereof |
| 01/11/2012 | CN101824394B Streptococcus suis II-type subunit vaccine and application thereof |
| 01/11/2012 | CN101780273B Vibrio harveyi secretory type vaccine and construction method thereof |
| 01/11/2012 | CN101775372B Anti-testicle-protein hT279 antibody or antibody fragment and application thereof |
| 01/11/2012 | CN101675922B Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 01/11/2012 | CN101638438B Human epididymis protease profilin immunological contraception polypeptide |
| 01/11/2012 | CN101544962B EV virus wide spectrum monoclonal antibody and its uses |
| 01/11/2012 | CN101326195B 抗il-17抗体 Anti-il-17 antibody |
| 01/11/2012 | CN101307317B Method for preparing rabies virus antigen |
| 01/11/2012 | CN101108250B Mono- and disaccharide derivatives |
| 01/11/2012 | CN101048176B Liquid allergy vaccine formulation for oromucosal administration |
| 01/10/2012 | US8093364 Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| 01/10/2012 | US8093362 p53 apoptosis effector related to PMP-22 (PERP) specific immunoglobulin for use in treatment and prevention of cell proliferative disorders |
| 01/10/2012 | US8093361 Anti-perp antibody |
| 01/10/2012 | US8093353 Screening compounds which disrupt the association of helices with cytoplasmic membranes |